Evidence map›Paper›PMID 41530870›Full record

ArticleGenome medicine2026

Multimodal-based analysis of single-cell ATAC-seq data enables highly accurate delineation of clinically relevant tumor cell subpopulations.

Kewei Xiong, Wei Wang, Ruofan Ding, Dinglin Luo, Yangmei Qin, Xudong Zou, Jiguang Wang, Chen Yu, Lei Li

Abstract read
In one paragraph

Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kewei Xiong *Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, 518055, China.
Wei Wang *Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, 518055, China.
Ruofan DingInstitute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, 518055, China.
Dinglin LuoInstitute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, 518055, China.
Yangmei QinInstitute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, 518055, China.
Xudong ZouInstitute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, 518055, China.
Jiguang WangDivision of Life Science, Department of Chemical and Biological Engineering, State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
Chen YuInstitute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, 518055, China. yu@szbl.ac.cn.
Lei LiInstitute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, 518055, China. lei.li@szbl.ac.cn.

Funding

National Natural Science Foundation of China 32370721National Natural Science Foundation of China 32570730Shenzhen Medical Research Fund C2503001
6 · The paper itself

Abstract

backgroundAccurately identifying functionally distinct tumor cell subpopulations remains a critical challenge in cancer research. While single-cell epigenomics assays provide powerful insights into tumor heterogeneity beyond gene expression, computational limitations have hindered their application.

methodsWe introduce Multimodal-based Analysis of scATAC-Seq data (MAAS), a method that integrates chromatin accessibility, copy number variations (CNVs), and single-nucleotide variants (SNVs) to identify functional tumor cell subpopulations. MAAS employs a self-expressive multimodal matrix factorization approach with rigorous coverage normalization and data denoising. We applied MAAS to simulated datasets and multiple real-world tumor scATAC-seq datasets, including pediatric ependymoma, B-cell lymphoma, and glioblastoma, and benchmarked its performance against existing integration methods. Functional relevance of subpopulation-specific genes was experimentally validated using gene knockdown and overexpression assays. Furthermore, we constructed subpopulation-specific gene regulatory networks and developed a prognostic signature from the key regulatory genes.

resultsMAAS demonstrated superior accuracy in detecting clinically relevant subpopulations, particularly in tumors with limited CNV heterogeneity, such as pediatric ependymoma and B-cell lymphoma. In glioblastoma, MAAS uncovered a previously unrecognized subpopulation with temozolomide resistance and further experimentally validated the effects of its signature genes through gene knockdown and overexpression. The MAAS-derived prognostic signature, MAASig, outperformed traditional clinicopathologic features across multiple cancer types when applied to independent validation cohorts.

conclusionsBy integrating multimodal information from scATAC-seq data, MAAS provides the robust identification of functionally distinct tumor cell subpopulations, facilitating the discovery of potential therapeutic targets.

Indexed as

Chromatin Immunoprecipitation SequencingNeoplasmsSingle-Cell AnalysisDNA Copy Number VariationsGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansPolymorphism, Single NucleotidePrognosisDrug resistanceMultimodal analysisPrognostic signatureScATACTumor heterogeneity

Identifiers

PMID41530870
PMCPMC12888741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.